Compare Divis Laboratories with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs UNICHEM LAB - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES UNICHEM LAB DIVIS LABORATORIES/
UNICHEM LAB
 
P/E (TTM) x 32.6 62.8 52.0% View Chart
P/BV x 7.4 0.7 1,090.1% View Chart
Dividend Yield % 0.6 2.1 29.7%  

Financials

 DIVIS LABORATORIES   UNICHEM LAB
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-18
UNICHEM LAB
Mar-19
DIVIS LABORATORIES/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs1,142292 391.0%   
Low Rs533182 292.9%   
Sales per share (Unadj.) Rs146.6167.7 87.4%  
Earnings per share (Unadj.) Rs33.0-3.6 -909.9%  
Cash flow per share (Unadj.) Rs38.45.9 646.4%  
Dividends per share (Unadj.) Rs10.004.00 250.0%  
Dividend yield (eoy) %1.21.7 70.8%  
Book value per share (Unadj.) Rs222.8372.3 59.9%  
Shares outstanding (eoy) m265.4770.38 377.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x5.71.4 404.2%   
Avg P/E ratio x25.3-65.3 -38.8%  
P/CF ratio (eoy) x21.839.9 54.7%  
Price / Book Value ratio x3.80.6 590.3%  
Dividend payout %30.3-110.2 -27.5%   
Avg Mkt Cap Rs m222,31816,680 1,332.8%   
No. of employees `00010.82.6 413.6%   
Total wages/salary Rs m4,5612,393 190.6%   
Avg. sales/employee Rs Th3,616.04,535.2 79.7%   
Avg. wages/employee Rs Th423.8919.8 46.1%   
Avg. net profit/employee Rs Th814.9-98.2 -829.8%   
INCOME DATA
Net Sales Rs m38,91511,801 329.8%  
Other income Rs m1,134984 115.3%   
Total revenues Rs m40,04912,785 313.3%   
Gross profit Rs m12,617-835 -1,511.2%  
Depreciation Rs m1,425674 211.5%   
Interest Rs m1375 17.7%   
Profit before tax Rs m12,313-600 -2,053.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,543-343 -1,031.6%   
Profit after tax Rs m8,770-256 -3,432.1%  
Gross profit margin %32.4-7.1 -458.3%  
Effective tax rate %28.857.3 50.2%   
Net profit margin %22.5-2.2 -1,040.8%  
BALANCE SHEET DATA
Current assets Rs m45,35120,384 222.5%   
Current liabilities Rs m6,5075,029 129.4%   
Net working cap to sales %99.8130.1 76.7%  
Current ratio x7.04.1 171.9%  
Inventory Days Days127105 120.9%  
Debtors Days Days95135 70.5%  
Net fixed assets Rs m21,1609,023 234.5%   
Share capital Rs m531141 377.1%   
"Free" reserves Rs m58,62526,058 225.0%   
Net worth Rs m59,15626,199 225.8%   
Long term debt Rs m00-   
Total assets Rs m67,83231,496 215.4%  
Interest coverage x926.8-7.0 -13,288.1%   
Debt to equity ratio x00-  
Sales to assets ratio x0.60.4 153.1%   
Return on assets %12.9-0.6 -2,261.6%  
Return on equity %14.8-1.0 -1,520.0%  
Return on capital %20.8-2.0 -1,042.2%  
Exports to sales %069.4 0.0%   
Imports to sales %21.80-   
Exports (fob) Rs mNA8,188 0.0%   
Imports (cif) Rs m8,485NA-   
Fx inflow Rs m32,3598,188 395.2%   
Fx outflow Rs m9,042596 1,517.2%   
Net fx Rs m23,3177,592 307.1%   
CASH FLOW
From Operations Rs m7,759-3,278 -236.7%  
From Investments Rs m-4,783-2,860 167.2%  
From Financial Activity Rs m-3,142-24 12,981.8%  
Net Cashflow Rs m-166-4,690 3.5%  

Share Holding

Indian Promoters % 52.0 50.1 103.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 15.1 78.1%  
FIIs % 19.0 3.0 633.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 31.7 54.3%  
Shareholders   31,796 20,176 157.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   PROCTER & GAMBLE HEALTH  CIPLA  TORRENT PHARMA  SUVEN LIFESCIENCES  WYETH LTD  

Compare DIVIS LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (1QFY20); Net Profit Up 0.4% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.4% YoY). Sales on the other hand came in at Rs 11 bn (up 14.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

UNICHEM LAB Announces Quarterly Results (1QFY20); Net Profit Up 102.2% (Quarterly Result Update)

Jul 30, 2019 | Updated on Jul 30, 2019

For the quarter ended June 2019, UNICHEM LAB has posted a net profit of Rs 5 m (up 102.2% YoY). Sales on the other hand came in at Rs 2 bn (up 15.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

UNICHEM LAB 2018-19 Annual Report Analysis (Annual Result Update)

Jul 4, 2019 | Updated on Jul 4, 2019

Here's an analysis of the annual report of UNICHEM LAB for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of UNICHEM LAB. Also includes updates on the valuation of UNICHEM LAB.

UNICHEM LAB Announces Quarterly Results (4QFY19); Net Profit Up 31.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, UNICHEM LAB has posted a net profit of Rs 37 m (up 31.7% YoY). Sales on the other hand came in at Rs 3 bn (up 35.1% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY19); Net Profit Up 10.6% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 10.6% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Sep 20, 2019 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - PIRAMAL ENTERPRISES COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS